The US FDA has approved a new non-opioid painkiller, Journavx, by Vertex Pharmaceuticals, which targets pain signals before reaching the brain to provide relief for moderate to severe pain without the addictive potential of opioids. Clinical trials showed effectiveness in reducing post-surgery pain, marking an important milestone in acute pain management amidst the opioid crisis in the US. Priced at $15.50 per capsule, Journavx is the first new class of pain medicine approved in over 20 years, offering hope for the 80 million Americans prescribed pain medication annually.
Full Article
Loading PerspectiveSplit analysis...
